Elenestinib
- Generic Name
- Elenestinib
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29FN10O
- CAS Number
- 2505078-08-8
- Unique Ingredient Identifier
- 6FBM4CP6RK
- Background
Elenestinib is a selective KIT inhibitor.
Blueprint Medicines Announces Positive BLU-808 Phase 1 Data and 2025 Growth Strategy
• Blueprint Medicines projects a $4 billion peak revenue opportunity for its systemic mastocytosis (SM) franchise, driven by AYVAKIT's success and updated SM prevalence estimates.
• Phase 1 trial results for BLU-808, an oral wild type KIT inhibitor, showed a wide therapeutic window and significant tryptase reductions, supporting its potential in allergic and inflammatory diseases.
• The company anticipates achieving $2 billion in AYVAKIT revenue by 2030 and is initiating proof-of-concept studies for BLU-808 in various allergic and inflammatory conditions.
• Blueprint Medicines has initiated a Phase 3 trial of elenestinib in indolent systemic mastocytosis (ISM) and is advancing CDK2 and CDK4 targeted protein degraders for breast cancer.
Avapritinib Demonstrates Long-Term Benefits in Advanced Systemic Mastocytosis
• Avapritinib (AYVAKIT) shows significant survival benefits in treatment-naïve patients with advanced systemic mastocytosis (SM) compared to midostaurin in real-world outcomes.
• Data from the PATHFINDER trial indicates that avapritinib leads to sustained improvements in bone density for advanced SM patients with low bone mass.
• Ultra-sensitive KIT testing identifies previously undetected KIT mutations in indolent systemic mastocytosis (ISM) patients, suggesting a higher disease prevalence.
• A predictive model using machine learning distinguishes between advanced SM and ISM with high accuracy, validated by an independent dataset from Dana-Farber Cancer Institute.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath